Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TAK-062 in Celiac Disease
NCT05353985Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Therapeutic Enzymes
- Countries
- 8
01
Overview
A Phase 2 trial of zamaglutenase in celiac disease, sponsored by Takeda. Started Jun 2022; status: completed.
02
Drugs
zamaglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT05353985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353985.